Quote: “Success in any one of our mid-phase trials could instantly transform the Company overnight,” commented Cellceutix Chief Executive Officer Leo Ehrlich. “Having already engaged in productive discussions with large pharmaceutical companies, Cellceutix remains partnership-focused in 2017. Potentially life-saving drugs and tremendous value creation await patients and shareholders alike as we strive to deliver compelling trial results.”
It doesn't take a rocket scientist to figure out that Cramer bought in at a low prices before the company and the CTIX stock price shoots up overnight.
Cramer is known to play the stock both ways. Cramer is an admitted stock manipulator.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.